within Pharmacolibrary.Drugs.ATC.G;

model G03XC05
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.5,
    Cl             = 0.00015266666666666667,
    adminDuration  = 600,
    adminMass      = 60 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.416,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0028,
    Tlag           = 10.020000000000001
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>G03XC05</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Ospemifene is a selective estrogen receptor modulator (SERM) approved for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy due to menopause. It is used orally in postmenopausal women and is currently approved and used in medical practice.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported from studies in healthy postmenopausal women after oral administration of 60 mg ospemifene tablets.</p><h4>References</h4><ol><li><p>Koskimies, P, et al., &amp; Scheinin, M (2013). Oral bioavailability of ospemifene improves with food intake. <i>International journal of clinical pharmacology and therapeutics</i> 51(10) 787–794. DOI:<a href=&quot;https://doi.org/10.5414/CP201873&quot;>10.5414/CP201873</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24040848/&quot;>https://pubmed.ncbi.nlm.nih.gov/24040848</a></p></li><li><p>Koskimies, P, et al., &amp; Scheinin, M (2013). Single-dose and steady-state pharmacokinetics of ospemifene, a selective estrogen receptor modulator, in postmenopausal women. <i>International journal of clinical pharmacology and therapeutics</i> 51(11) 861–867. DOI:<a href=&quot;https://doi.org/10.5414/CP201925&quot;>10.5414/CP201925</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24075094/&quot;>https://pubmed.ncbi.nlm.nih.gov/24075094</a></p></li><li><p>Preston, RA, et al., &amp; Graham, S (2015). The effect of renal and hepatic impairment on the pharmacokinetics of ospemifene, a tissue-selective estrogen agonist/antagonist. <i>American journal of therapeutics</i> 22(3) 171–181. DOI:<a href=&quot;https://doi.org/10.1097/01.mjt.0000434044.39502.64&quot;>10.1097/01.mjt.0000434044.39502.64</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24413373/&quot;>https://pubmed.ncbi.nlm.nih.gov/24413373</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end G03XC05;
